Nicola Mason is an Associate Professor in the Department of Clinical Sciences and Advanced Medicine and holds the Paul A. James and Charles A. Gilmore Endowed Chair Professorship at the University of Pennsylvania’s School of Veterinary Medicine. She received her veterinary degree from the Royal Veterinary College, London and her Immunology PhD from the University of Pennsylvania. She performed her post doctoral fellowship in the lab of Carl June at the Abramson Cancer Center at the School of Medicine at UPenn. Dr. Mason’s translational research group focuses on developing safe and effective immunotherapies for use in dogs with cancer, autoimmunity and infectious disease. Her work pioneering the translation of a live, recombinant HER2 targeting Listeria in dogs with osteosarcoma earned her the One Health Award for Excellence in promoting One Health Initiatives and Interprofessional Education. Her research interests include adoptive immunotherapy using CAR T cells in canine patients with B cell lymphoma and glioblastoma, the use of CAAR T cells in autoimmune disease and the development of therapeutic monoclonal antibodies. More recently her lab has developed an interest in transplant immunology and in the induction of graft tolerance using adoptive cell therapies. Through comparative medicine her work aims to accelerate the clinical translation of effective immunotherapies, improving the lives of both humans and dogs. Dr. Mason leads the canine cancer immunotherapy consortium known as PRECINCT, that is supported by the Beau Biden Cancer Moonshot initiative and her research is funded through federal and private foundation grants.